We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

By LabMedica International staff writers
Posted on 10 Jan 2025

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company Innovaccer Inc. More...

(San Francisco, CA, USA) with the aim of improving patient outcomes and experience through novel digital and diagnostic solutions. The investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.

Innovaccer has developed a suite of software solutions designed to create a unified patient record to identify gaps in care and patients at risk, as well as appropriate interventions to improve patient outcomes. As part of the investment partnership, Danaher, along with Innovaccer and its network of healthcare systems, aims to accelerate the adoption of precision diagnostics both by clinicians and population health teams, facilitating value-based care.

"Patients are at the center of everything we do at Danaher. We believe our investment partnership with Innovaccer will empower patients and speed the transition to more personalized, value-based medicine by providing healthcare providers with the data and analytics needed to drive meaningful clinical insights, more quickly, and at the point of need," said Julie Sawyer Montgomery, Executive Vice President, Danaher Corporation.

"Danaher is committed to ethically using AI to develop and deliver better diagnostics to help doctors treat their patients with the right medicine in the right dose at the right time," said Murali Venkatesan, Head of Danaher Ventures, Americas & Europe and Vice President of Science, Technology and Innovation, Danaher Corporation. "We're excited to connect our innovation ecosystem with Innovaccer's to enable this healthcare transformation."

"At Innovaccer, we are on a mission to improve health outcomes through our data platform and AI capabilities," said Abhinav Shashank, cofounder and CEO of Innovaccer. "We believe that partnering with Danaher will accelerate our efforts to advance diagnostic and clinical AI solutions."

Related Links:
Danaher Corporation
Innovaccer Inc.


New
Gold Member
Hybrid Pipette
SWITCH
Portable Electronic Pipette
Mini 96
Hemodynamic System Monitor
OptoMonitor
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.